Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Non-cash Items (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Non-cash Items for 4 consecutive years, with $6.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-cash Items fell 59.71% to $6.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $6.2 million, a 59.71% decrease, with the full-year FY2024 number at $16.1 million, down 8.09% from a year prior.
  • Non-cash Items was $6.2 million for Q3 2025 at Century Therapeutics, roughly flat from $6.2 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $38.4 million in Q1 2023 to a low of $2.8 million in Q2 2022.
  • A 4-year average of $13.2 million and a median of $15.5 million in 2024 define the central range for Non-cash Items.
  • Peak YoY movement for Non-cash Items: surged 1007.31% in 2023, then tumbled 69.49% in 2025.
  • Century Therapeutics' Non-cash Items stood at $3.2 million in 2022, then skyrocketed by 446.75% to $17.6 million in 2023, then fell by 8.09% to $16.1 million in 2024, then tumbled by 61.33% to $6.2 million in 2025.
  • Per Business Quant, the three most recent readings for IPSC's Non-cash Items are $6.2 million (Q3 2025), $6.2 million (Q2 2025), and $5.7 million (Q1 2025).